Live Breaking News & Updates on Miliary|Page 5

Stay updated with breaking news from Miliary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

NuCana plc: NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis NUC-3373 Continues Rapid Development with Multiple Data Readouts ....

United Kingdom , City Of , Jenniferj Knox , Hughs Griffith , Marion Janic , Chris Brinzey , Data Monitoring Committee Recommended Study , Data Monitoring Committee , Exchange Commission , University Of Toronto , Company Annual Report On Form , Princess Margaret Cancer Centre , Rapid Development , First Interim , Multiple Data Readouts , First Patients , Cancer Study Expected , Lymphoma Study , Data Readouts Expected Throughout , Independent Data Monitoring Committee , Blinded Independent Central Review , Chief Executive , Clinician Investigator , Chief Investigator , Private Securities Litigation Reform Act , Annual Report ,

NuCana plc: NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study

Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022 First Interim Analysis of 418 Evaluable Patients Remains on Track for the First Half of 2022 Data ....

United States , United Kingdom , City Of , Hughs Griffith , Marion Janic , Chris Brinzey , Company Annual Report On Form , Exchange Commission , Approval Program , Patients Expected , Enable Second Interim Analysis , Second Half , Interim Analysis , Patients Remains , First Half , Either Interim Analysis May Support , Objective Response Rate , Chief Executive , Overall Survival , Private Securities Litigation Reform Act , Annual Report ,

AstraZeneca: New Data In Liver, Biliary Tract, Prostate Cancer Treatment With Imfinzi And Lynparza

LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) announced Thursday new data in liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza.The company noted that ....

United States , City Of , United Kingdom , Dave Fredrickson , Cancers Symposium , Executive Vice President , Oncology Business Unit ,

GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership . | December 17, 2021 ....

France General , United States , Hong Kong , United Kingdom , Fanny Allaire , Pascal Prigent , Jess Smith , David Loew , Ipsen Euronext , Stephanie Boyer , Global Communications , European Commission , Drug Administration , Terns Pharmaceuticals , Head Of Global Communications , European Medicines Agency , Globenewswire Inc , Business Development , Primary Biliary Cholangitis , Breakthrough Therapy Designation , Orphan Drug Designation , Medicines Agency , Chief Executive Officer , Breakthrough Therapy , Rare Disease , Total Sales ,

Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

Agreement gives Ipsen global rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational ....

France General , United States , Hong Kong , United Kingdom , Fanny Allaire , Pascal Prigent , Jess Smith , David Loew , Ipsen Euronext , Global Communications , European Commission , Uncertainties Of The Company , Drug Administration , Terns Pharmaceuticals , Exchange Commission , Head Of Global Communications , European Medicines Agency , Stephanie Boyer , Business Development , Primary Biliary Cholangitis , Breakthrough Therapy Designation , Orphan Drug Designation , Chief Executive Officer , Biliary Cholangitis , Breakthrough Therapy , Rare Disease ,